Experience with the use of baricitinib in the treatment of atopic dermatitis in HIV-infected patients

Background. Among HIV-infected patients, atopic dermatitis (AD) occurs more frequently by 30% than in patients without HIV infection, and is characterized by severe dermatological symptoms and severe skin itch. For this reason, the treatment of AD and pruritus in HIV-infected patients remains relevant. Objective. Evaluation of the possibility of using the baricitinib in HIV-infected patients with AD. Methods. 6 HIV-infected patients with AD were followed-up; all patients received antiretroviral therapy (ART). There were 4 men (66.7%), 2 women (33.3%). The median age was 32.7 years (21-43). The mean duration of AD was 14.5 years (min - 7.1 years, max - 22). SCORAD - 74.8 (min - 28, max - 89). The mean duration of HIV infection was 3.8 years (min - 0.7 years, max - 11 years), the duration of ART averaged 3.4 years (min - 0.5 years, max - 9.6). All patients were examined before prescribing baricitinib. Results. In HIV-infected patients with AD, a pronounced clinical improvement in the general condition, a significant decrease in skin itching, and a decrease in the intensity of dermatological symptoms were noted after 12 weeks. There was no deterioration in the indicators of HIV infection (clinical course, decrease in the number of CD4+ lymphocytes, an increase in the viral load of HIV). Conclusion. Baricitinib in HIV-infected patients can be used for the treatment moderate to severe AD.

HIV infection, atopic dermatitis, baricitinib